Dermata Therapeutics (DRMA) Q2 2025 earnings summary

Executive summary

• Report covers the quarter ended June 30, 2025, for a late-stage dermatology-focused biotech developing Spongilla-based therapies for acne and other skin conditions.

• Lead candidate XYNGARI™ met all co-primary endpoints in the Phase 3 STAR-1 acne trial, showing statistically significant efficacy over placebo at both 4 and 12 weeks.

• No revenue generated; operations funded by equity and warrant financings, raising $8.8 million in gross proceeds in H1 2025.

• Cash runway expected into Q2 2026, but substantial doubt exists about ability to continue as a going concern without additional capital.

• Initiated additional manufacturing and planning for the Phase 3 STAR-2 trial and a 9-month extension study.

Financial highlights

• Net loss for Q2 2025 was $1.7 million, improved from $2.8 million in Q2 2024.

• Cash and cash equivalents totaled $6.5 million as of June 30, 2025, up from $3.2 million at December 31, 2024.

• Operating expenses for Q2 2025 were $1.8 million, down from $2.9 million in Q2 2024, mainly due to lower clinical trial costs.

• Research and development expenses for Q2 2025: $0.6 million, down from $2.0 million in Q2 2024.

• General and administrative expenses for Q2 2025: $1.2 million, up from $0.9 million in Q2 2024, driven by higher compliance and personnel costs.

Outlook and guidance

• Cash expected to fund operations into Q2 2026; additional capital will be needed to complete Phase 3 studies and pursue further development.

• Plans to focus on regulatory approval and commercialization of XYNGARI™ for acne, and further development of DMT410.

• Planning to initiate the Phase 3 STAR-2 trial for XYNGARI™ and a Phase 2a study with DMT410 for axillary hyperhidrosis.

• Ongoing evaluation of strategic transactions, partnerships, and additional financings.